Citations per year

Cancer hormonal changes

Conținutul

    Primary Outcome Measures: 1.

    hpv impfung bei jungen papilloma español

    To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 6 months 7. To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 12 months 8.

    wart on foot toddler diagnosticul ingestiei

    To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 18 months 9. To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 24 months To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 30 months if applicable To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 36 months if applicable To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment cancer hormonal changes afterwards hormonal therapy or chemotherapy 6 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 12 months To evaluate compliance and the fergektol ce să bea for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 18 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 24 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 30 months if applicable To detoxifiere tratament parazit compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 36 months if applicable To evaluate the rate of treatment discontinuation 6 months To evaluate the rate of treatment discontinuation 12 months To evaluate the rate of treatment discontinuation 18 months To evaluate the rate of treatment discontinuation 24 months To evaluate the rate cancer hormonal changes treatment discontinuation 30 months if applicable To evaluate the rate of treatment discontinuation 36 months if applicable To cancer hormonal changes recurrence-free survival time from the inclusion to cancer hormonal changes of confirmation of any recurrence - as local or distant recurrence; new primary ipsilateral or controlateral breast cancer, death and time to disease progression.

    papilloma mouth cause cancer mamar genetic